Terminalia chebula (haritaki) and joint comfort

What 2 graded rows on terminalia chebula (haritaki) agree on for joint comfort, and where they differ. Counted side by side, never averaged.

Consensus finder Rows from the Terminalia chebula (haritaki) page, reviewed Oct 21, 2026 How it decides

What the rows agree on

Each block and row is one graded row from the Terminalia chebula (haritaki) page, with its PubMed record.

Supplement

Terminalia chebula (haritaki) Choose another

2 rows · 117 people

They agree: both rows found an improvement.

No difference

Improved

Each block is one evidence row, sized by how many people it enrolled, with its grade inside.

From the rows

The best-graded row, grade D, is a randomized trial of 105 people (2017) and found an improvement.

The rows run from 12 to 105 people, published from 2016 to 2017: 2 single studies.

2 improved

Grade DKnee comfort, function and walking in overweight adults · Improved
RCT · n 105 · 2017 · Overweight adults aged 35–70 with knee discomfort only during activity (USA)
250 mg or 500 mg twice daily · 84 days
Versus placebo, mKOOS global scores improved; knee discomfort with activity, whole-body joint function and 6-minute walk distance improved relative to baseline. The two doses did not differ on most outcomes.
Row on the Terminalia chebula (haritaki) page · PubMed 28969626 (opens PubMed)
Grade DPain threshold and tolerance in a lab pain test · Improved
Crossover RCT · n 12 · 2016 · Healthy volunteers (India)
1,000 mg single dose (two 500 mg capsules) · Single dose, tested at 3 hours
Pain threshold rose about 21% and pain tolerance about 13% versus placebo in a mechanical pressure test; no adverse reactions.
Row on the Terminalia chebula (haritaki) page · PubMed 27625480 (opens PubMed)